Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's Drank Melatonin Warning Echoes Liquid Supplement Draft Guidance

This article was originally published in The Tan Sheet

Executive Summary

FDA's warning to a firm marketing a melatonin-containing beverage yields early evidence of how the agency intends to enforce provisions of its draft guidance on liquid dietary supplements

You may also be interested in...



Relaxation Potion Warning: Wake Up Call About FDA Beverage Guidance

FDA warning letter on Dewmar’s Lean Slow Motion…Potion line is the first addressing differences between products marketed as conventional beverages and as liquid supplements since a final guidance in January. Attorney Justin Prochnow says the warning could signal an FDA crackdown on melatonin in conventional beverages.

Relaxation Potion Warning: Wake Up Call About FDA Beverage Guidance

FDA warning letter on Dewmar’s Lean Slow Motion…Potion line is the first addressing differences between products marketed as conventional beverages and as liquid supplements since a final guidance in January. Attorney Justin Prochnow says the warning could signal an FDA crackdown on melatonin in conventional beverages.

Durbin Bill Would Narrow Definition Of Dietary Supplement

Legislation Sen. Dick Durbin offers to stop firms from allegedly side-stepping food safety standards by labeling products as dietary supplements could have a "devastating impact on the industry," stakeholders say.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS103870

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel